<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198978</url>
  </required_header>
  <id_info>
    <org_study_id>GMALL02</org_study_id>
    <nct_id>NCT00198978</nct_id>
  </id_info>
  <brief_title>German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Multicenter Study To Optimize Treatment in Elderly Patients (&gt; 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the
      treatment of elderly patients with acute lymphoblastic leukemia. In patients with expression
      of CD20 on leukemic cells the efficacy and tolerability of additional application of
      Rituximab together with chemotherapy is evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Anticipated">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate (cytologic, Remission rate (molecular), Survival time, Duration of Remission, Toxicity (CTC, Treatment realization</measure>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adult Acute Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone / Prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-Colony-Stimulating Factor</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDARAC</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depocyte</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acute lymphoblastic leukemia (pro B, pre B, c-ALL or T-ALL), proved by
             morphology and immunophenotyping

          -  Age &gt; 55 yrs (no upper age limit)

          -  Written informed consent

        Exclusion Criteria:

          -  Severe leukemia associated complications, not controllable before therapy onset e.g.

          -  life threatening infections as sepsis, pneumonia, hypoxia, shock, life threatening
             bleeding)

          -  Severe comorbidity e.g.

          -  decompensated renal failure if not caused by leukemia with Creatinine &gt; 2x ULN

          -  heart failure (NYHA II/IV), instable Angina, significant coronary stenosis

          -  hepatic insufficiency e.g. liver cirrhosis or chronic active hepatitis with bilirubin
             &gt; 1,5 x ULN and/or ASA, ALA, AP &gt; 2,5 ULN

          -  decompensated metabolic disturbances (e.g. not controllable diabetes)

          -  severe obstructive or restrictive pulmonary disease with hypoxaemia

          -  Severe psychiatric illness or other circumstances which may compromise cooperation of
             the patient

          -  Active second neoplasia

          -  HIV infection

          -  Severely reduced general condition

          -  Cytostatic pre-treatment of ALL

          -  Chemotherapy treatment of any other malignancy during the last 5 years

          -  Participation in other clinical trials interfering with the study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Hoelzer, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Frankfurt, Medical Dept. II</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dieter Hoelzer, MD,PhD</last_name>
    <phone>++49(0)69 6301 5194</phone>
    <email>hoelzer@em.uni-frankfurt.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicola Goekbuget, MD</last_name>
    <phone>++49(0)69 6301 6365</phone>
    <email>goekbuget@em.uni-frankfurt.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Frankfurt, Medical Dept. II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Hoelzer, MD,PhD</last_name>
      <phone>++49(0)6963015194</phone>
      <email>hoelzer@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Goekbuget, MD</last_name>
      <phone>++49(0)6963016365</phone>
      <email>goekbuget@em.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dieter Hoelzer, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Goekbuget, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leukemia-trials.eu</url>
    <description>European Leukemia Trial Registry</description>
  </link>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>June 4, 2008</last_update_submitted>
  <last_update_submitted_qc>June 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2008</last_update_posted>
  <keyword>ALL</keyword>
  <keyword>Treatment</keyword>
  <keyword>Elderly</keyword>
  <keyword>De novo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

